https://www.selleckchem.com/pr....oducts/cremophor-el.
From 2017 to 2019, of the 17 patients who were managed with a WW approach, 13 patients have remained regrowth free after a median of 28 (13-58) months of WW. Preliminary findings suggest management with WW, following cCR, may be a safe alternative to TME. There have so far been no instances of distant failure, and those with cCR that had regrowth, were identified early and successfully managed with salvage TME. Preliminary findings suggest management with WW, following cCR, may be a safe alternative to TME. Ther
Like
Comment
Share
